# Christian U. Blank

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/christian-u-blank/

## Facts

| Field | Value |
| --- | --- |
| Citations | 60,525 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 96 |
| i10-index | 281 |
| Last Known Institution | Leiden University Medical Center |
| OpenAlex ID | https://openalex.org/A5088390068 |
| ORCID iD | https://orcid.org/0000-0002-7945-5846 |
| Works | 670 |

## Researcher papers

- [Genomic correlates of response to CTLA-4 blockade in metastatic melanoma](https://scholariq.org/papers/genomic-correlates-of-response-to-ctla-4-blockade-in-metastatic-melanoma/)
- [B cells and tertiary lymphoid structures promote immunotherapy response](https://scholariq.org/papers/b-cells-and-tertiary-lymphoid-structures-promote-immunotherapy-response/)
- [The human tumor microbiome is composed of tumor type–specific intracellular bacteria](https://scholariq.org/papers/the-human-tumor-microbiome-is-composed-of-tumor-type-specific-intracellular/)
- [Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma/)
- [Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma](https://scholariq.org/papers/integrative-molecular-and-clinical-modeling-of-clinical-outcomes-to-pd1-blockade/)
- [Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma](https://scholariq.org/papers/reversible-and-adaptive-resistance-to-braf-v600e-inhibition-in-melanoma/)
- [Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma](https://scholariq.org/papers/tumor-infiltrating-lymphocyte-therapy-or-ipilimumab-in-advanced-melanoma/)
- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)
- [ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee](https://scholariq.org/papers/esmo-consensus-conference-recommendations-on-the-management-of-metastatic/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [Leiden University Medical Center](https://scholariq.org/institutions/leiden-university-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.